{"id":823247,"date":"2025-03-07T16:33:26","date_gmt":"2025-03-07T21:33:26","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cellectis-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-13-2025\/"},"modified":"2025-03-07T16:33:26","modified_gmt":"2025-03-07T21:33:26","slug":"cellectis-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-13-2025","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cellectis-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-13-2025\/","title":{"rendered":"Cellectis to Report Fourth Quarter and Full Year 2024 Financial Results on March 13, 2025"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">NEW YORK, March  07, 2025  (GLOBE NEWSWIRE) &#8212; Cellectis\u00a0(the \u201cCompany\u201d) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the fourth quarter and full year 2024 ending December 31, 2024 on Thursday, March 13, 2025 after the close of the US market.<\/p>\n<p align=\"justify\">The publication will be followed by an investor conference call and webcast on Friday, March 14, 2025, at 8:00 AM ET \/ 1:00 PM CET. The call will include the Company\u2019s fourth quarter and full year 2024 results and an update on business activities. Details for the call are as follows:<\/p>\n<p align=\"justify\">\n        <strong>Dial in information:<\/strong>\n      <\/p>\n<p align=\"justify\">Domestic: +1-800-225-9448<\/p>\n<p align=\"justify\">International: +1-203-518-9708<\/p>\n<p align=\"justify\">Conference ID: CLLS24<\/p>\n<p>Webcast Link: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=gEsHsRXVrMfWo9n4zwZXf5HLi4itH1FL-Cp1qfedoHZ3iLpOh7YLLXGZILnnSsjEIV7mkz6EX7FSZUPOz9_sg4gK6RNaz6rRQhcM7_wHjHFQd7FU7SNIppsFywfFoUzF8bLwSnuE8GD-ZGu-wCJIScW2GXDcsm4sJuIu_-1s1n7M2gpCvRumZCIpIH5b-snX8cSqugQ1g-SUsp-Zbk9BgHBq_06lHV70yyicgbgiV2h8AjZsc-49GQ5SfxysEMI6RSZY_-TVWF0VXjZV2X-n1hg4Y4UI0Qb3gv7WS-0TrpuFbXMvK1OerlE1T27XZTzW4tBzg5vo38AbeudxokiLr214xWLcNaJgoFY_1P7BLK8n0kyl5aqMpOfG7qQh_avBSBJvP2FeyHr3IFD-1JB0YoL6waMh3B3Tu9bwYUKY9eWRi3B3IbUyF-6iomrSWtQzS9e9RdTsmb4Mul2xkFzqMuk6T9RwIzID-Ra1im9B24n5tv2EiXzLHKQ6ln6_eAjooXMonEzrRniPooytaSJ7E1wQxcSz69YQiUHHP05l7MI3ZjIdN3IvdSgiyf4qBA6v_YHn-1s1Lb2u7uMjA4w7qPfTZb429tWYpvXme_0i0qAxl_fwu0Z7kxIQEuPVDL8PKi8CLLciHfpW1zRTZFuAvIpIYsnj6VlUaW9yLDtc0CrOcenfkLpBvoqAKla4CfjbgpnQSuQlG3vUZzU_URuLVK2-WfzcvD-dFGYankP2QwQ1n4GtgRScDJEFR9VgxYzd\" rel=\"nofollow\" target=\"_blank\"><u>https:\/\/viavid.webcasts.com\/starthere.jsp?ei=1706599&amp;tp_key=4524940f8f<\/u><\/a><\/p>\n<p>\n        <strong>About Cellectis<\/strong>\u00a0\u00a0\u00a0\u00a0\u00a0<\/p>\n<p align=\"justify\">Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. The company utilizes an allogeneic approach for CAR T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to develop gene therapies in other therapeutic indications. With its in-house manufacturing capabilities, Cellectis is one of the few end-to-end gene editing companies that controls the cell and gene therapy value chain from start to finish.<\/p>\n<p align=\"justify\">Cellectis\u2019 headquarters are in Paris, France, with locations in New York and Raleigh, NC. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS).\u00a0To find out more, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=oLbFhjz1VXle__nM2Sxd2Ac4DL3TH5mmJzeQsHjoBdYi4nVyBaZOc78JVjoOxUZZOkiOwBletFacXAkb2EAYnmwwqCc-UEGQcv3qBiQINV4=\" rel=\"nofollow\" target=\"_blank\"><u>www.cellectis.com<\/u><\/a> and follow Cellectis on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zbdkdVTRfDWbDDcLlTovsAI_HTLh7xB6lD_Cd4glyqpF7QAnSNLyXrvZ4Is-OAUSl_Zt_DaRPI4lR3MlaWXPK2rcDYqERwRWoMvZxclajMvqMP3IDXTSaInAQQ-xpXN-EDuEN2GwZRHzk2lr2uh_yw==\" rel=\"nofollow\" target=\"_blank\"><u>LinkedIn<\/u><\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=2-fXkudeCpqCIennr71GqmaQHZlh3dqBpT8oFNnLVgGHpivS2AKaMN9hu9hqcwRp-ELwANM9aosjf7scYlgwVA==\" rel=\"nofollow\" target=\"_blank\"><u>X<\/u><\/a>.<\/p>\n<p align=\"justify\">TALEN\u00ae is a registered trademark owned by Cellectis.\u00a0<\/p>\n<p>\n        <strong>For further information on Cellectis, please contact:<\/strong>\u00a0\u00a0\u00a0\u00a0\u00a0<\/p>\n<p align=\"justify\">\n        <strong>Media contacts:<\/strong>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<\/p>\n<p align=\"justify\">Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=8hNHjHL3s4Q4OSfHhU9aXf3S5xogchlmfdwQdJGCqHXg_w6b1iY5c_mF1jErpsKY7etX4d0JfUnIfHKa3Fn8BFp5MIfiwqF9FMWH2OhFG-Q=\" rel=\"nofollow\" target=\"_blank\"><u>media@cellectis.com<\/u><\/a><\/p>\n<p align=\"justify\">Patricia Sosa Navarro, Chief of Staff to the CEO,\u00a0+33 (0)7 76 77 46 93<\/p>\n<p align=\"justify\">\n        <strong>Investor Relations contact:<\/strong>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<\/p>\n<p align=\"justify\">Arthur Stril, Chief Financial Officer &amp; Chief Business Officer, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0-WwvhgFcsqxUhTf12W0p8lBzGBfsUBWV5QrYZegFI3dlYGryIvPtrTJkZV53t-ovO7dXAUnRwI9Ip3d5MSL_JegADFzGL1LLpWAciX64jWQAeRSLtgaiD6GoY1TKGG0\" rel=\"nofollow\" target=\"_blank\">investors@cellectis.com<\/a>\u00a0 \u00a0 \u00a0 \u00a0<\/p>\n<p id=\"gnw_attachments_section-header\">\n        <strong>Attachment<\/strong>\n      <\/p>\n<ul id=\"gnw_attachments_section-items\">\n<li>\n          <a href=\"https:\/\/ml.globenewswire.com\/Resource\/Download\/594d8e05-a98f-4664-91d5-3bbbc657fb64\" rel=\"nofollow\" target=\"_blank\">20250307_FY 2024 earnings call announcement_ENGLISH<\/a>\n        <\/li>\n<\/ul>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5MDc4NCM2Nzk1NjQ0IzIwNDk4Nzc=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MDIxOTkwMzItNmQzYS00YWJiLTkxMTgtYzE1NjA4OWU0NTE1LTEwNjE0NDgtMjAyNS0wMy0wNy1lbg==\/tiny\/Cellectis-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW YORK, March 07, 2025 (GLOBE NEWSWIRE) &#8212; Cellectis\u00a0(the \u201cCompany\u201d) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the fourth quarter and full year 2024 ending December 31, 2024 on Thursday, March 13, 2025 after the close of the US market. The publication will be followed by an investor conference call and webcast on Friday, March 14, 2025, at 8:00 AM ET \/ 1:00 PM CET. The call will include the Company\u2019s fourth quarter and full year 2024 results and an update on business activities. Details for the call are as follows: Dial in information: Domestic: +1-800-225-9448 International: &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cellectis-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-13-2025\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Cellectis to Report Fourth Quarter and Full Year 2024 Financial Results on March 13, 2025&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-823247","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Cellectis to Report Fourth Quarter and Full Year 2024 Financial Results on March 13, 2025 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cellectis-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-13-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cellectis to Report Fourth Quarter and Full Year 2024 Financial Results on March 13, 2025 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, March 07, 2025 (GLOBE NEWSWIRE) &#8212; Cellectis\u00a0(the \u201cCompany\u201d) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the fourth quarter and full year 2024 ending December 31, 2024 on Thursday, March 13, 2025 after the close of the US market. The publication will be followed by an investor conference call and webcast on Friday, March 14, 2025, at 8:00 AM ET \/ 1:00 PM CET. The call will include the Company\u2019s fourth quarter and full year 2024 results and an update on business activities. Details for the call are as follows: Dial in information: Domestic: +1-800-225-9448 International: &hellip; Continue reading &quot;Cellectis to Report Fourth Quarter and Full Year 2024 Financial Results on March 13, 2025&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cellectis-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-13-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-07T21:33:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5MDc4NCM2Nzk1NjQ0IzIwNDk4Nzc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cellectis-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-13-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cellectis-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-13-2025\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Cellectis to Report Fourth Quarter and Full Year 2024 Financial Results on March 13, 2025\",\"datePublished\":\"2025-03-07T21:33:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cellectis-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-13-2025\\\/\"},\"wordCount\":327,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cellectis-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-13-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5MDc4NCM2Nzk1NjQ0IzIwNDk4Nzc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cellectis-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-13-2025\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cellectis-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-13-2025\\\/\",\"name\":\"Cellectis to Report Fourth Quarter and Full Year 2024 Financial Results on March 13, 2025 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cellectis-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-13-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cellectis-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-13-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5MDc4NCM2Nzk1NjQ0IzIwNDk4Nzc=\",\"datePublished\":\"2025-03-07T21:33:26+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cellectis-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-13-2025\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cellectis-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-13-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cellectis-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-13-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5MDc4NCM2Nzk1NjQ0IzIwNDk4Nzc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5MDc4NCM2Nzk1NjQ0IzIwNDk4Nzc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cellectis-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-13-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cellectis to Report Fourth Quarter and Full Year 2024 Financial Results on March 13, 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cellectis to Report Fourth Quarter and Full Year 2024 Financial Results on March 13, 2025 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cellectis-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-13-2025\/","og_locale":"en_US","og_type":"article","og_title":"Cellectis to Report Fourth Quarter and Full Year 2024 Financial Results on March 13, 2025 - Market Newsdesk","og_description":"NEW YORK, March 07, 2025 (GLOBE NEWSWIRE) &#8212; Cellectis\u00a0(the \u201cCompany\u201d) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the fourth quarter and full year 2024 ending December 31, 2024 on Thursday, March 13, 2025 after the close of the US market. The publication will be followed by an investor conference call and webcast on Friday, March 14, 2025, at 8:00 AM ET \/ 1:00 PM CET. The call will include the Company\u2019s fourth quarter and full year 2024 results and an update on business activities. Details for the call are as follows: Dial in information: Domestic: +1-800-225-9448 International: &hellip; Continue reading \"Cellectis to Report Fourth Quarter and Full Year 2024 Financial Results on March 13, 2025\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cellectis-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-13-2025\/","og_site_name":"Market Newsdesk","article_published_time":"2025-03-07T21:33:26+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5MDc4NCM2Nzk1NjQ0IzIwNDk4Nzc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cellectis-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-13-2025\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cellectis-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-13-2025\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Cellectis to Report Fourth Quarter and Full Year 2024 Financial Results on March 13, 2025","datePublished":"2025-03-07T21:33:26+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cellectis-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-13-2025\/"},"wordCount":327,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cellectis-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-13-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5MDc4NCM2Nzk1NjQ0IzIwNDk4Nzc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cellectis-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-13-2025\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cellectis-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-13-2025\/","name":"Cellectis to Report Fourth Quarter and Full Year 2024 Financial Results on March 13, 2025 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cellectis-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-13-2025\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cellectis-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-13-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5MDc4NCM2Nzk1NjQ0IzIwNDk4Nzc=","datePublished":"2025-03-07T21:33:26+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cellectis-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-13-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cellectis-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-13-2025\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cellectis-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-13-2025\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5MDc4NCM2Nzk1NjQ0IzIwNDk4Nzc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5MDc4NCM2Nzk1NjQ0IzIwNDk4Nzc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cellectis-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-13-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Cellectis to Report Fourth Quarter and Full Year 2024 Financial Results on March 13, 2025"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/823247","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=823247"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/823247\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=823247"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=823247"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=823247"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}